Vladimir Tolstikov, Ph.D., is Director of Metabolomics at BERG. He received B.S. and M.S in Organic Chemistry in 1977 from M.V. Lomonosov Institute of Fine Chemical Technology, in Moscow, Russia. He received Ph.D. in Organic Chemistry in 1983 from the Institute of Chemical Means for Plant Protection, Moscow, Russia. He is a pioneer in HILIC separations development applied to Metabolomics. During his career he was working in leading research institutions in USA, Germany, Hungary and Russian Federation. He has joined Eli Lilly and Company in 2012. He is author contributor and participant of 45 conferences, 5 book chapters, and 54 articles

Metabolomics, Systems Biology

Mishra received his B. S (Honors) and M.S degrees from Patna University ( then nicknamed as Oxford of the East) in India and Ph. D Degree from McMaster University. He received his post –doctoral training with the late Nobel Laureate Professor E. L. Tatum at the Rockefeller University. He was a Fellow for Medical Research of the Jane Coffin Child Fund of the Yale University at the Rockefeller University for two years and then Research Associate with Professor Tatum where he initiated his work in what is now called as Proteomics and Matabolomics.

Biological Sciences

Narendra Yadav Demonstrated success in biotechnology, including two once-in-a-lifetime breakthroughs: 1) Discovered omega 6 desaturase gene that led to the biotech soybean oil Plenish® benefitting farmers (anticipated to be the 4th largest U.S. row crop by 2023), the food industry, and consumers with its zero trans fat oil (“In a Bean, a Boon to Biotech”, New York Times, Nov 15, 2013).2) Engineered yeast into the richest source of omega-3 fatty acids, described by Nature Biotechnology as a ‘metabolic-engineering tour de force’. Its use in VerlassoTM salmon replaced 75% of the wild-caught fish needed in aquaculture to earn the distinction of “better alternative” by Seafood Watch. Inventor on 63 granted patents.  Author on 23 peer-reviewed papers in high impact journals.  Successful metabolic engineering of one plant and two microbes from start to finish and all worked!  Genetically engineered both central and secondary metabolic pathways in plants and microbes.  Genome editing in plants and microbes as well as in their organelles (mitochondria and chloroplasts).  Demonstrated expertise in bioinformatics, gene discovery, cutting edge DNA assembly.  high throughput, automated microbe engineering using Benchling platform and robots, such as Mantis, Bravo, Guava, Tecan, and Fragment Analyzer.

Synthetic Biology

Dr. Bryan earned his undergraduate Bachelor of Science degree in Biochemistry from the University of Texas at Austin and his doctoral degree from Louisiana State University School of Medicine in Shreveport where he was the recipient of the Dean’s Award for Excellence in Research. He pursued his post-doctoral training as a Kirschstein Fellow at Boston University School of Medicine in the Whitaker Cardiovascular Institute. After a two year post-doctoral fellowship, in 2006 Dr. Bryan was recruited to join faculty at the University of Texas Health Science Center at Houston by Ferid Murad, M.D., Ph.D., 1998 Nobel Laureate in Medicine or Physiology. During his tenure as faculty and independent investigator at UT, his research focused on drug discovery through screening natural product libraries for active compounds. His nine years at UT led to several discoveries which have resulted in eight issued US and international patents and nine pending worldwide. Specifically, Dr. Bryan was the first to describe nitrite and nitrate as indispensable nutrients required for optimal cardiovascular health. He was the first to demonstrate and discover an endocrine function of nitric oxide via the formation of S-nitrosoglutathione and inorganic nitrite. Through the drug discovery program in natural product chemistry, Dr. Bryan discovered unique compositions of matter than can be used to safely and effectively generate and restore nitric oxide in humans. This technology is now validated in six published clinical trials and Dr. Bryan has 9 issued US and International patents. He is also a successful entrepreneur who has successfully commercialized his nitric oxide technology through a UT portfolio company, named to the Inc 5000 fastest growing companies in the US for the past 3 years straight. Dr. Bryan has been involved in nitric oxide research for the past 16 years and has made many seminal discoveries in the field. These discoveries and findings have transformed the development of safe and effective functional bioactive natural products in the treatment and prevention of human disease and may provide the basis for new preventive or therapeutic strategies in many chronic diseases. Dr. Bryan has published a number of highly cited papers and authored or edited 5 books. He is an international leader in molecular medicine and nitric oxide biochemistry.

Biochemistry

Gerald C. Hsu received an honorable PhD in mathematics and majored in engineering at MIT. He attended different universities over 17 years and studied seven academic disciplines. He has spent 20,000 hours in T2D research. First, he studied six metabolic diseases and food nutrition during 2010-2013, then conducted research during 2014-2018. His approach is “math-physics and quantitative medicine” based on mathematics, physics, engineering modeling, signal processing, computer science, big data analytics, statistics, machine learning, and AI. His main focus is on preventive medicine using prediction tools. He believes that the better the prediction, the more control you have.

Preventive medicine using prediction tools

Boris Zaslavsky graduated in Analytical Chemistry from the Moscow State University. He holds a PhD and a DSc (USSR Academy of Sciences), was a scientist at USSR Academy of Sciences (1971-1991), Visiting Fellow at Cornell University Medical School (NYC, 1991-1992), and KV Pharmaceuticals (1993-1994), Argonne National Laboratory (1994-1995). He is the founder of Analiza, Inc. (1996-present) and Cleveland Diagnostics (2014-present), where serves as a Chief Scientific Officer. He published 1 monograph, over 120 scientific papers, and 7 patents. His research interests are development of analytical applications of aqueous two-phase partitioning, new clinical tests for early cancer detection and other applications, role of water in biology, and protein-water interactions.

Systems Biology

Xuanxian Peng is a Professor, School of Life Sciences, Sun Yat-Sen University, China. He received his Ph.D. from Xiamen University, China and studied at McGill University, Canada as a postdoctoral fellow. Professor Peng was the first Dean of School of Life Sciences, Xiamen University, China from 1999 to 2003. He was a member of the fifth Chinese Education Ministry for Sciences and Technology and vice chairmen of Chinese Society for Marine Biochemistry and Molecular Biology. His research focuses on functional metabolomics for antibiotic resistance, which have recently been published in Cell Metabolism and PNAS

Functional metabolomics for antibiotic resistance

Dr Ivan Minic, student of Academic Doctoral studies, Dental science, department of Oral medicine and Parodontology, Medical faculty, University of Nis, Serbia. I participated in several international congresses, the author of more than 25 scientific papers, a member of the editorial board of over 30 journals and reviews over 15 journals.

Dr Ivan Minic is interested in Oral medicine, Parodontology, Oral parology, drug investigation, biomedical science, metabolic disease.

Petra Perner is the founder and director of the Institute of Computer Vision and Applied Computer Sciences in Leipzig, Germany. Under her leadership the institute developed to one of the leading institutes in basic and applied research in computer vision, data mining, machine learning, case-based reasoning and image databases. She received a diploma degree in electrical engineering in 1981 and a PhD degree in computer science in 1985. In 1989 she finished her habilitation entitled “A Methodology for the Development of Knowledge-Based Image-Interpretation Systems”. Under her guidance highly qualified national and international personnel got trained in the above mentioned high-technology fields through research projects and education programs. The tutorial on Data Mining (www.data-mining-tutorial.de) is a recognized tutorial among the domain experts and is especially designed for training industrial people on hot topics in data mining. She gave courses on Data Mining and Image Interpretation at different universities in various countries. She has been the project leader and principal investigator of various national and international research projects for which she received several research awards. Her projects are marked by the fact that they tie together high-class research with the aspect of the economic application. She is frequently invited as a guest professor for knowledge-based image inspection systems by several national and international institutes and companies. She supervised the foundation of two high-technology companies named ibai-solutions (www.ibai-solutions.de) and ImageInterpret GmbH (www.imageinterpret.de) whose teams received 4 distinct business prices for transferring image-interpretation and data-mining methods to industry. She was the principal founder and chairwoman of the Technical Committee “Machine Learning and Data Mining”. She is the chairwoman of three distinct conferences in Machine Learning, Data Mining and High-Content Analysis of Signals and Images called MLDM (www.mldm.de), ICDM (www.data-mining.forum.de) and MDA (www.mda-signals.de). Presently she is working on various medical, chemical and biomedical applications, information management applications, technical diagnosis and e-commerce applications. Most of the developments are protected by legal patent rights and can be licenced to qualified industries. She has published numerous scientific publications and patents and is frequently requested as pleanary speaker in distinct research fields as well as across disciplinces. Her vision is to build intelligent flexible and robust data-interpreting systems that are inspired by the human case-based reasoning process.

Research Interest Applied Computer Science, Data Mining

Prof. Xia is the Dean of the School of Public Health, Nanjing Medical University, Vice Director of Center for Global Health and the PI of State Key Laboratory of Reproductive Medicine and Key Laboratory of Modern Toxicology of the Ministry of Education. His current research interests are Systems Biology and Environmental Health. He has been using high-throughput techniques to profile human environmental exposure and biological responses to exogenous chemicals. Prof. Xia has presided over more than ten national and ministerial projects, including the State Key Program of National Natural Science Foundation of China and the National Outstanding Youth Science Foundation. He has been the Committee Member of several domestic and international academic organizations. Prof. Xia has published over 110 peer-reviewed articles, and got 7 national invention patents. He also serves as the editor and reviewer of more than 20 international journals.

Systems Biology and Environmental Health.

Hui Li is a Professor, School of Life Sciences, Sun Yat-Sen University, China. She received her Ph.D. from Sichuan University, China and studied at Sun Yat-sen University,China as a postdoctoral fellow. Her research focuses on functional metabolomics for antibiotic resistance, which have recently been published in Cell Metabolism and PNAS

Functional metabolomics for antibiotic resistance

Bo Peng has his expertise in metabolic regulation of antibiotic resistance. His research focuses on the elucidation of the metabolic features antibiotic-resistant bacteria He proposed that antibiotic-resistant bacteria have their metabolomes, naming antibiotic-resistance metabolome (ARM). The crucial biomarkers identified from ARM could reverts the ARM to antibiotic-sensitive metabolome (ASM), which increase the killing efficacy of antibiotics to multidrug-resistant bacteria, biofilm-forming bacteria and persisters (Peng et al, Cell metabolism, 2015). This strategy is also applicable to enhance host immune response to infections through metabolic regulations. Thus, this approach provides a novel strategy to fight against antibiotic-resistant bacteria in a greener but efficient way.

Elucidation of the metabolic features antibiotic-resistant bacteria

Gerald C. Hsu received an honorable PhD in mathematics and majored in engineering at MIT. He attended different universities over 17 years and studied seven academic disciplines. He has spent 20,000 hours in T2D research. First, he studied six metabolic diseases and food nutrition during 2010-2013, then conducted research during 2014-2018. His approach is “math-physics and quantitative medicine” based on mathematics, physics, engineering modeling, signal processing, computer science, big data analytics, statistics, machine learning, and AI. His main focus is on preventive medicine using prediction tools. He believes that the better the prediction, the more control you have.

Preventive medicine using prediction tools

Leads scientific laboratory using structural biology tools including NMR spectroscopy to discover protein ligands, functions and exploitation routes. Specialization in proteins involved in membrane recognition, genetic diseases, oncoproteins and microbial pathogenesis. Interests in drug discovery, membrane nanoparticles, and technologies for understanding and exploiting interactions of proteins and organelles.

Specialties: structural biology, NMR spectroscopy, drug discovery, cancer mechanisms, SME collaborations, industrial partnerships, scientific infrastructure, regional and city strategic development

Mishra received his post –doctoral training with the late Nobel Laureate Professor E. L. Tatum at the Rockefeller University and Ph. D Degree from McMaster University.He received his B. S and M.S degrees from Patna University ( then nicknamed as Oxford of the East) in India. Later he joined the University of South Carolina Molecular Biology Group and Chairman of the Microbiology dept in the Medical School and remained as Professor of Genetics in the Dept. of Biological Sciences. He was also a Visiting Professor at the Max Planck Institute for Molecular Biology in Heidelberg, Germany and in Genetic Institute of Greenwood, SC. In addition to a large number of articles published in leading journals, he has published two books by John Wiley & Sons of New York, one on Proteomics in 2010; this book has been endorsed by Nobel Laureate Professor Gunter Blobel. Dr Mishra is also on the Board of Journal, Proteomics & Bioinformatics.

Metabolomics & Proteomics

Boris Zaslavsky graduated in Analytical Chemistry from the Moscow State University. He holds a PhD and a DSc (USSR Academy of Sciences), was a scientist at USSR Academy of Sciences (1971-1991), Visiting Fellow at Cornell University Medical School (NYC, 1991-1992), and KV Pharmaceuticals (1993-1994), Argonne National Laboratory (1994-1995). He is the founder of Analiza, Inc. (1996-present) and Cleveland Diagnostics (2014-present), where serves as a Chief Scientific Officer. He published 1 monograph, over 120 scientific papers, and 7 patents. His research interests are development of analytical applications of aqueous two-phase partitioning, new clinical tests for early cancer detection and other applications, role of water in biology, and protein-water interactions.

Systems Biology

Petra Perner (IAPR Fellow) is the director of the Institute of Computer Vision and Applied Computer Sciences IBaI in Leipzig, Germany. She received her Diploma degree in electrical engineering and her PhD degree in computer science for the work on “Data Reduction Methods for Industrial Robots with Direct Teach-in-Programing”. Her habilitation thesis was about “A Methodology for the Development of Knowledge-Based Image-Interpretation Systems". She has been the principal investigator of various national and international research projects. She received several research awards for her research work and has been awarded with 3 business awards for her work on bringing intelligent image interpretation methods and data mining methods into business.

Computational Systems Biology

K. Ogata has completed his PhD at the age of 27 years from Yokohama City University in 1992 and postdoctoral studies from RIKEN tsukuba institute. In 1997, He became the leader of the regulation of protein function project, Kanagawa Academy of Science and Technology (KAST), and from 2001,the professor and chair person of Department of Biochemistry, Yokohama City University Graduate School of Medicine.He has published papers in JMB, PNAS, NSMB, and Cell, and had been serving as an editorial board member of BBRC (2009-2010)

Metabolomics

Tao Huang has been the Director of Bioinformatics Core Facility at Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences since 2014. From 2012 to 2014, he was a Postdoctoral Fellow at Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York City, USA. His research interests include bioinformatics, computational biology, systems genetics and big data research. He has published over 100 articles in peer-reviewed journals. His works have been cited for 3138 times with an h-index of 26 and an i10-index of 64. He has been independent reviewer for about 30 journals. He is Editor for Book Computational Systems Biology - Methods and Protocols of Springer, Guest Editor for BBA Molecular Basis of Disease, BBA General Subjects, Artificial Intelligence in Medicine, BioMed Research International, Combinatorial Chemistry & High Throughput Screening and Computational and Mathematical Methods in Medicine.

Bioinformatics

Dr. Vladimir Bondarenko is Assistant Professor at Georgia State University, USA. He did his Ph.D. Physics and Mathematics, Moscow State University , Russia , 1990. Dr. Bondarenko's research interests include dynamical systems, neuronal and cardiac cell models, neural networks, models of cardiac arrhythmias, ion channel models.

Systems Biology

Toshio Suda is an MD from Yokohama City University School of Medicine. He was Professor of the Department of Cell Differentiation at Kumamoto University School of Medicine, now he is Professor of Developmental Biology at Keio University. Toshio Suda and others identified the niche for hematopoietic stem cells and subsequently established the new field of oxidative stress and stem cell aging. The interaction of stem cells and niche is one of hot topics for the stem cell and cancer biology.

1. Manipulation of the hematopoietic stem cell (HSC) niche for the ex vivo expansion of HSCs 2. Elucidation of niche involvement in the pathophysiology of hematopoietic malignancies along with the identification of molecular targets of diseases. 3. Identification of stemness-related cis-regulatory elements 4. Establishment of human stem cell niche in immunodeficient mouse

Vladimir Tolstikov, Ph.D., is Director of Metabolomics at BERG. He received B.S. and M.S in Organic Chemistry in 1977 from M.V. Lomonosov Institute of Fine Chemical Technology, in Moscow, Russia. He received Ph.D. in Organic Chemistry in 1983 from the Institute of Chemical Means for Plant Protection, Moscow, Russia. He is a pioneer in HILIC separations development applied to Metabolomics. During his career he was working in leading research institutions in USA, Germany, Hungary and Russian Federation. He has joined Eli Lilly and Company in 2012. He is author contributor and participant of 45 conferences, 5 book chapters, and 54 articles

Metabolomics, Systems Biology

Houkai Li has completed his PhD at the age of 32 years from Shanghai Jiao Tong University and Postdoctoral studies from University of North Carolina (2011.8-2013.5) and Chinese Academy Sciences (2008.11-2011.3) respectively. He is now a Professor at Center for Traditional Chinese Medicine and Systems Biology in Shanghai University of Traditional Chinese Medicine. He has published over 22 papers in reputed journals.

Metabolomics and Systems Biology

Ching-Wan Lam obtained his MBChB from The Chinese University of Hong Kong in 1991 and FRCPA in 1997 from The Royal College of Pathologists of Australasia with a double scope of practice in Chemical Pathology and Genetics. He is a Fellow of The Australasian Association of Clinical Biochemists’. He obtained his PhD in 2000 from The Chinese University of Hong Kong. He obtained FRCP(Glas) from The Royal College of Physicians and Surgeons of Glasgow in 2012.
Ching-Wan Lam is a chemical pathologist with 20 years experiences in inherited metabolic disease and has over 160 publications on this subject. His research interests include various aspects of inherited metabolic diseases and genetic testing. For example, he identified the MECP2 gene, the first disease gene for non-syndromic infantile autism. The locus is called AUTSX3 (AUTISM, X-LINKED, SUSCEPTIBILITY TO, 3; MIM ID #300496). This work has been incorporated in the formulation of an international guideline for etiologic diagnosis of autism, i.e, The American College of Medical Genetics 2013 clinical practice guideline.
He identified the SMOOTHENED gene to be the driver gene in sporadic medulloblastomas. This work has provided important leads for development of SMOOTHENED inhibitor Vismodegibs. He also identified a new pharmacogenetic disease in which valproate, a first-line anti-epilepsy drug, can trigger onset of Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes (MELAS). This work has lead to a change in clinical practice that valproate is now contraindicated to patients with mitochondrial DNA disease by Food and Drug Administration (FDA),The United States of America
Ching-Wan Lam is The Editor, Clinical Chimica Acta, an official journal of The International Federation of Clinical Chemistry and Laboratory Medicine.

The elucidation of the molecular basis of inherited human diseases through the identification of disease-causing genes. The development of molecular diagnostics through the identification of the mutation spectrum of disease-causing genes. Provides an effective DNA-based diagnostic protocol suitable for the 1.3-billion Chinese populations worldwide.

Dr. Alan Prem Kumar, Bsc., Msc., Ph.D. serves as Member of Scientific Advisory Board and Member of Business Development Advisory Board at GenoMed, Inc. Following his postdoctoral years, Dr. Kumar joined the Faculty of Medicine, National University of Singapore as an independent Principal Investigator to continue on his expertise on nuclear receptor and cancer biology. From a commercialization perspective, he co-filed a patent on a new potent PPARgamma ligand for treatment of diabetes and cancer. Dr. Kumar has also successfully set up a Singapore-USA collaboration agreement (covering patent issues as well) for another 16 new derivatives drugs - activators and inhibitors of PPARgamma for treatment of diabetes and cancer, thence to a clinical trial here in Singapore. In addition, he has also set up research collaboration between NUS and his collaborator in the USA to identify new synthetic ligands for HNF4alpha and PPARdelta for translation into the clinic. Over the years, Dr. Kumar and his laboratory have forged several relationships with scientists in cancer research and with cancer advocacy groups in Singapore. Dr. Kumar then made a research focus switch from Microbiology to pursue Postdoctoral training in Cancer Research at Sidney Kimmel Cancer Center, California, USA with Dr. Wanda Reynolds. He was awarded a Postdoctoral Fellowship for his work on the role of nuclear receptors in the transcriptional regulation of human myeloperoxidase, a leukocyte enzyme implicated as causative agent in atherosclerosis and Alzheimer's disease. Dr. Kumar earned his BSc, MSc, and Ph.D. in Molecular Biology from University of North Texas, USA. From his Ph.D. work, he discovered a novel regulatory protein, PyrR for the pyrimidine biosynthetic pathway in Pseudomonas.

Diabetes and cancer are common diseases among adults worldwide. New research shows that both hyperinsulinaemia and hyperglycemia, characteristics of type 2 diabetes, are major risk factors for a number of cancer-promotes tumor development. My area of research focuses on exploring the role of nuclear receptors, such as PPARs (peroxisome proliferator-activated receptors), ERα, HNF4α, and DEAD-box RNA helicases in the prevention and treatment of cancer and diabetes.

Paul M. Yen is Professor at Duke-NUS Graduate Medical School in Singapore and Head of the Laboratory of Hormonal Regulation in the Cardiovascular and Metabolic Disorders Program. He obtained his M.D. from Johns Hopkins, completed his residency in internal medicine at University of Chicago and his endocrinology fellowship at NIH. Prior to Duke-NUS he served on the faculty at Johns Hopkins, Harvard, and as section chief at NIDDK, NIH. He has served on the editorial boards of Endocrinology, Molecular Endocrinology, and Thyroid. His current research interests are hormonal regulation of hepatic autophagy and lipid metabolism in non-alcoholic fatty liver disease as well as epigenetic regulation of metabolic genes by thyroid hormone.

Cardiovascular & Metabolic Disorders

Takao Shimizu graduated from Medical School at the University of Tokyo, and took postgraduate course at Kyoto University and Karolinska Institutet, Stockholm. He was appointed as an Associate Professor of Biochemistry and Nutrition, in 1984, and a full professor of Biochemistry and Molecular Biology in 1991. He served as a Dean of Medical School at the University of Tokyo since 2007, and Vice President of the University since 2011. He is currently a professor of the University of Tokyo (Lipidomics laboratory), and director of National Center for Global Health and Medicine (lipid signaling).

Lipid mediators. Knockout mouse study. Phospholipid metabolism. Lipidomics. LC-MS

Shazib Pervaiz obtained his medical degree (M.B.B.S.) in 1985 from King Edward Medical College, Lahore, Pakistan, and his Ph.D. in 1992 from Southern Methodist University and Baylor University Medical Center, Dallas, TX. He was a fellow in the department of Pathology and later at the Cancer Center at Harvard Medical School/MGH, Boston, MA from 1992-96. Following a short stint at Millennium Pharmaceuticals Inc., Cambridge, MA, he joined the National University of Singapore, Singapore, where he currently holds a Full Professorship in the department of Physiology, Yong Loo Lin School of Medicine. He has held various leadership positions at the YLL School of Medicine, such as Vice Dean (Research and Graduate Education) and Director, National University Medical Institutes (2003- 06). Dr. Pervaiz also holds a joint professorship at the Duke-NUS Graduate Medical School, Singapore and is a member of the Duke-NUS Cancer and Stem Cell Biology Program. He is also an affiliate member of the National University Cancer Institute, NUHS, Singapore, and is a senior faculty at the NUS Graduate School for Integrative Sciences and Engineering and the Singapore-Massachusetts Institute of Technology (MIT) Alliance. Dr. Pervaiz has also served on the scientific advisory board of Behring Diagnostics, Inc., Westwood, MA (1995-96) and more recently of AutoGenomics Inc., Carlsbad, CA and CellWorks Group Inc., San Jose, CA.

Cross talk between mitochondria and caspase in apoptotic signaling -Regulation of apoptosis by Reactive Oxygen Species -Regulation of death signaling by Bcl-2 family -Oncogenic signaling and reactive oxygen species -Inflammation and cancer -Photoactivation: novel modality for drug discovery

Simona Di Francesco is the Director of Urological, Biomedical and Translational Sciences Department. People's University Nicolaus Copernicus , Cassino (RM) ,Italy 2014 M.D , PhD. People's University Nicolaus Copernicus , Cassino (RM) ,Italy 2014 PhD Degree in Clinical and Experimental Medicine and Surgery (CEMS), School of Advanced Studies , Department of Medicine and Aging, University “G. D’Annunzio” Chieti-Pescara. Doctoral Thesis : Metabolic Alterations and Vascular Damage in Prostate Cancer. 2012 AWARD-PIERRE FABRE-CIFU, Italian Society of Urology. 2012 Project Planning Course , G. D’Annunzio University of Chieti-Pescara, School of Advanced Studies. 2012 Advanced English Course For Special Purposes. G. D’annunzio University. School of Advanced Studies. 2012 Course Of Scientific English "Writing Across Science”, G. D’annunzio University, School of Advanced Studies, Nazareth College. 2011 Course Scientific English - Uda-Learning , G. D’Annunzio University of Chieti-Pescara. 2010 Specialization in Urology, G. D’Annunzio University of Chieti-Pescara, with maximum marks cum laude. 2009 Specialization in Internist Echography, G. D’Annunzio University of Chieti-Pescara. 2004 Urostage: Kidney , Prostate, Urinary Bladder. University “G. D’Annunzio” Chieti-Pescara, Department of Medicine and Aging, Section of Urology. 2001 XIV International Course of Digestive and Endocrine Surgery. University “G. D’Annunzio” Chieti-Pescara, School of Medicine and Surgery, Italy. 2001-2002 M.D, G.D’Annunzio University of Chieti-Pescara, Medicine and Surgery.

Simona Di Francesco research interest is in Urological Cancer and Immunology, Prostate and Immunology, Bladder and Immunology, Kidney and Immunology.

Choon Nam ONG is the Director of the NUS Environmental Research Institute (NERI) and a professor at the Saw Swee Hock School of Public Health, National University of Singapore. He has published more than 300 papers in international peer-reviewed journals with an h-index of 75, and over 17,000 citations. His main research interest is Environmental Health Sciences and teaches in Toxicology and Environment Health, and nursing a lifelong passion of all matters related to environment on health. Since 1985, he has served as a consultant to the World Health Organization (WHO) on many occasions and was involved in 12 of its Health Criteria publications.He is an editorial board member of several international journals on environment and sustainability. He is a visiting professor to several overseas universities and serves as a Scientific Advisor to the China Center of Disease Control and Prevention (CDC). He was the recipient of Astra-Zeneca American Toxicology Society Award, 2002. Dr Ong also served as an advisor to the OECD, US National Water Research Institute, and has been consulted often by international health agencies on issues related to environmental health. He has been a member of the WHO Guidelines for Drinking Water Quality Expert Panel since 2003. His research group currently focuses on the use of metabolomics as a technology platform for biomedical and environmental research.

Environmental Health, Metabolomics, Toxicology

Vladimir Tolstikov, Ph.D., is Director of Metabolomics at BERG. He received B.S. and M.S in Organic Chemistry in 1977 from M.V. Lomonosov Institute of Fine Chemical Technology, in Moscow, Russia. He received Ph.D. in Organic Chemistry in 1983 from the Institute of Chemical Means for Plant Protection, Moscow, Russia. He is a pioneer in HILIC separations development applied to Metabolomics. During his career he was working in leading research institutions in USA, Germany, Hungary and Russian Federation. He has joined Eli Lilly and Company in 2012. He is author contributor and participant of 45 conferences, 5 book chapters, and 54 articles

Metabolomics, Mass Spectrometer, HPLC

Bjoern Riefke, Head of Metabolic Profiling and Clinical Pathology, Bayer Schering Pharma After the study of Biology and his PhD in Zoology/Animal Physiology at the Heinrich-Heine-University in Duesseldorf, Germany Bjoern Riefke started to work as a research fellow in 1994 at the Institute of Diagnostic Research in Berlin. His main research field was the biological characterization of dyes for near-infrared in-vivo imaging. In 1998 he followed an offer of Schering AG to lead a research group at Justesa Imagen S.A. in Madrid, Spain as assistant manager and head of biological research and development in the field of X-ray contrast media research. In 2003 he moved back to Bayer Health Care Berlin (former Schering AG) and headed the group of early and mechanistic toxicology with research support for the early detection of safety liabilities of drug candidates and one year later headed the group of clinical pathology with the establishment of metabolic profiling technology in toxicology. Since 2005 he participated in the validation of new biomarkers within the HESI Nephrotoxicity Working Group. Beside the routine support and project related work the main area of interest are the application of metabolic profiling in toxicology and in pharmacological studies and the evaluation of new biomarkers for different organ toxicities in comparison to traditional endpoints of clinical pathology and histopathology in the context of toxicology testing.

Metabolic Profiling and Clinical Pathology

Dr. Yoshiro Fujii is a director and chief dentist of Shin Kobe Dental Clinic. 1985:D.D.S. (Certified by Japanese Health Ministry).1989: He received Koide prize. Finished graduate school, Nagoya, Japan. and Ph.D (Aich Gakuin University Graduate school, Nagoya). 2000: Dr. Fujii began to run Shin Kobe Dental Clinic (Kobe, Japan). 2009: Fellow of the international college of acupuncture and electro-therapeutics (F.I.C.A.E). 2013,2014: 100 next era CEOs in Asia (Japan times). 2014: Editioriall board member of Savvy Science Publisher. 2015: Editorial board member of British Journal of Medical Research.. 2015: 100 Next-era Leaders in Asia (Japan times). He has written five published works in Japanese and two in English. He is an Authorization doctor of the Japan Bi-Digital O-Ring Test. Association and a director of the Japan Society of Dental Equipment. He published eleven international academic articles in English. 2014-15: He was a chair or co-chair three times in various international congresses.

Holistic Dentistry

Scott Tebbutt is Associate Professor in the Department of Medicine, Division of Respiratory Medicine, University of British Columbia, and Principal Investigator at the James Hogg Research Centre, Institute for Heart + Lung Health, St. Paul’s Hospital, Vancouver, Canada. Since 2006, he has served as Co-Director of the Molecular Phenotyping and Genotyping Core of the James Hogg Research Centre, and he is currently Director of the Technology Development Core. He is also Chief Scientific Officer of the Prevention of Organ Failure (PROOF) Centre of Excellence, focused on heart, lung and kidney failure. Dr. Tebbutt earned his B.A. degree in Biochemistry from the University of Oxford (Oriel College), England in 1989, and his Ph.D. in Molecular Genetics from the University of East Anglia in 1993 (supervised by Dr. David Lonsdale, Cambridge Laboratory, John Innes Centre, England). He pursued post-doctoral fellowships in the laboratories of Professor Ann Harris (University of Oxford, Institute of Molecular Medicine) and Professor Diana Hill (University of Otago, Dunedin, New Zealand), where he studied the molecular genetics of cystic fibrosis. He was appointed Research Fellow at the University of Otago (1995-2001), leading a research team investigating the genomics of the sheep cystic fibrosis locus. He was seconded to a start-up biotechnology company (Global Technologies (NZ) Ltd.) as Director of Genomics (1999-2001). He moved to Canada in 2001, and was Senior Researcher in the Centre for Biomedical Research (University of Victoria, 2001-2002), prior to being recruited to the James Hogg Research Centre (formerly the iCAPTURE Centre) at St. Paul’s Hospital, Vancouver (2002).

Dr. Tebbutt’s research programme is focused on the genomics of complex respiratory disease, including the early and late reactions in allergic asthma and rhinitis. He also leads a multidisciplinary collaboration to investigate interactions between fungal spores and human airway cells. His research combines hypothesis-driven study of biological mechanisms with the development of advanced tools and technology (including bioinformatics and microfluidics-based systems) to better facilitate basic and translational research. Dr. Tebbutt has published original research contributions in journals such as the Proceedings of the National Academy of Sciences (U.S.A.), Journal of Medical Genetics, Genomics, BioTechniques, Bioinformatics, BMC Bioinformatics, BMC Medical Genomics and PLoS ONE. He has published numerous technical reviews as well as book chapters on the role of genetic variation in respiratory disease. He has served as reviewer on several grant panels, including the Canadian Institutes of Health Research and the Michael Smith Foundation for Health Research, and he is Associate Editor for the journal BMC Genetics. Dr. Tebbutt has received several fellowships and awards, including an Edward Penley Abraham Research Trust Fellowship (U.K.), a Journal of Cell Science Traveling Fellowship Award, and a Research Fellowship from the Cystic Fibrosis Association of New Zealand. He has been awarded competitive research funding from organizations such as the National Sanitarium Association (Canada), the British Columbia Lung Association, AllerGen NCE Inc. (Allergy, Genes and Environment Network), the Canadian Institutes of Health Research, the BC Proteomics Network, and the Wellcome Trust (U.K.).

Houkai Li has completed his PhD at the age of 32 years from Shanghai Jiao Tong University and Postdoctoral studies from University of North Carolina (2011.8-2013.5) and Chinese Academy Sciences (2008.11-2011.3) respectively. He is now a Professor at Center for Traditional Chinese Medicine and Systems Biology in Shanghai University of Traditional Chinese Medicine. He has published over 22 papers in reputed journals.

Metabolomics and Molecular biology

Jagat Kanwar is an Associate Professor of Immunology & Cell Biology, and Group Leader in “Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research” at Deakin University, Australia. He did his PhD in 1993 from PGIMER, Chandigarh, India and worked as a Senior Scientist in The Auckland University, New Zealand for more than 10 years. He has a national and international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. His research is also focused on miRNA, aptamer, locked nucleic acid (LNA) LNA-modified chimeric aptamers-siRNA conjugates, and immunoliposomes technology and disease targeted drug discovery. His research combines Immunology with state of the art and cutting edge techniques in Molecular Biology, Biochemistry, Nanobiotechnology and visualization to investigate the pathways in which key molecules are regulated in both normal and disease states. He designed nanocarriers for applications in vaccines, immunotherapy, and drug delivery of antigens immunostimulatory ligands to dendritic cells and subsequent stimuli to T- lymphocytes, B-lymphocytes and TH17 cells.

Cancer and chronic inflammatory diseases targeted nanomedicine based drug delivery siRNA, miRNA anti-sense targeted gene nanomedicine based technology to target cancer and inflammation Drug discovery with anticancer targets for cancer cell survival, death, arrest, and repair Development of recombinant proteins and searching new immunomodulatory and anti-inflammatory bioactives, proteins and peptides for cancer and neuroprotection Development of complementary alternative medicine from the milk derived proteins including metal binding protein (Lactoferrin), and herbal preparation derived active components with a special focus on the treatment of colon and breast cancers Development of oral and intravenous administration of nanocarriers to overcome the challenging concept of drug resistance in various cancers Development of new generation safe, biodegradable, less toxic, disease targeted natural contrast materials for imaging Novel nano-medicinal based vaccines and immunotherapy Micro-fluidics and Lab-on-a-Chip devices for delivery and diagnosis

Professor Sam Li is a faculty member at the Department of Chemistry, National University of Singapore (NUS). He received his BSc, PhD and DSc degrees from Imperial College, UK. His research interests include environmental science and technology, metabolomics, biosensors and nanotechnology. He has authored/co-authored 325 publications in international peer review journals, more than 100 conference presentations and 10 US patents. He serves/served on editorial advisory boards of several international scientific journals, including Electrophoresis (Germany), Journal of Chromatographic Science (USA), LC-GC (Asia Pacific), and Biomedical Chromatography (UK).

Environmental science and technology, Metabolomics, Biosensors and Nanotechnology

Thomas W. Chittenden is a Theoretical Systems Biologist and Founder of the Complex Biological Systems Alliance, a global scientific think tank dedicated to furthering scientific understanding of biological complexity and the nature and origins of human disease. Tom serves as a Senior Biostatistician and Mathematical Biologist for the Research Computing Group at the Harvard Medical School and a Scientific Advisor for the Pathway Genomics Corporation. He is a Research Fellow at the Vertex Society, an Associate Member of the International Society for Philosophical Enquiry, and a Member of the New England Complex Systems Institute. Tom holds a PhD in Molecular Cell Biology and Biotechnology from Virginia Tech and a DPhil in Computational Biology and Bioinformatics from the University of Oxford. His multidisciplinary postdoctoral training includes experimental investigations in Molecular and Cellular Cardiology at the Dartmouth Medical School and Integrative Functional Genomics at the Dana-Farber Cancer Institute and the Harvard School of Public Health.

A major focus of Tom’s research involves development and application of integrated systems biology models to investigate evolutionary factors of human disease. His overall objective is to understand how genetic variation and somatic mutation regulate aberrant gene activity and subsequent disease biology. To this end, Tom spent a year as a Visiting Research Scientist in the Department of Statistics at the University of Oxford, where he formulated a general strategy for constructing prediction models by integrating a priori biological knowledge with multiple types of high-throughput genomic data. This approach improves performance of established classification methods via enhanced semantic interoperability for mapping between multiple biomedical ontologies and the subsequent identification of genes more highly predictive of disease etiology.

Dr. Vladimir E. Bondarenko is Associate Professor at Georgia State University, USA. He did his Ph.D. Physics and Mathematics, Moscow State University, Russia, 1990. Dr. Bondarenko’s research interests include dynamical systems, neuronal and cardiac cell models, neural networks, models of cardiac arrhythmias, ion channel models.

Dynamical systems, Neuronal and Cardiac cell models, Neural networks, Models of cardiac arrhythmias, Ion channel models.

Michel Aliani is an Associate Professor at the Department of Human Nutritional Sciences at the University of Manitoba and a member of the Canadian Centre for Agri-Food Research in Health and Medicine in Winnipeg, Manitoba. He was educated in France (B.Sc. and Engineering degree in Agri-Food Biochemistry) and in Northern Ireland (PhD, and Post-doctoral at Queen’s University Belfast) prior to move to University of Manitoba in 2007. His area of scientific expertise includes food science, mass spectrometry and metabolomics.

The focus of Dr. Aliani’s research is therefore twofold. 1.To provide the scientific and molecular basis for the development and successful marketing of functional foods targeted to patients as well as healthy populations in the world and 2.To investigate the effect of active compounds on metabolic pathways in animal and human model.

Dr. Deliang Guo is Assistant Professor at Ohio State University Comprehensive Cancer Center. His major research interests are tumor metabolism, autophagy and oncogenic signaling. His research is supported by multiple grants from NIH, American Cancer Society and American Brain Tumor Association.

Tumor metabolism, Autophagy and Oncogenic signaling

Chris Beecher is Chief Scientific Officer for IROA Technologies. He was a member of the Department of Pathology, University of Michigan School of Medicine until 2011 when he founded NextGen Metabolomics. He was also one of the founders of Metabolon, and Metabolic Analyses. His Ph.D. was granted in 1985 in Pharmaceutical Sciences specializing in Natural Products drug discovery. He has more than 25 years of experience in metabolomics and drug discovery and development, has published over 80 peer-reviewed papers, and is listed as the inventor of 8 patents in metabolomics.

Vladimir Tolstikov, Ph.D., is Scientist at Eli Lilly and Company. He received B.S. and M.S in Organic Chemistry in 1977 from M.V. Lomonosov Institute of Fine Chemical Technology, in Moscow, Russia. He received Ph.D. in Organic Chemistry in 1983 from the Institute of Chemical Means for Plant Protection, Moscow, Russia. He is a pioneer in HILIC separations development applied to Metabolomics. During his career he was working in leading research institutions in USA, Germany, Hungary and Russian Federation. He has joined Eli Lilly and Company in 2012. He is author contributor and participant of 45 conferences, 5 book chapters, and 54 articles.

He is an associate professor of pharmacology & toxicology.

Computational, analytical and statistical approaches for metabonomics and systems biology in human health

Bjoern Riefke, Head of Metabolic Profiling and Clinical Pathology, Bayer Schering Pharma After the study of Biology and his PhD in Zoology/Animal Physiology at the Heinrich-Heine-University in Duesseldorf, Germany Bjoern Riefke started to work as a research fellow in 1994 at the Institute of Diagnostic Research in Berlin. His main research field was the biological characterization of dyes for near-infrared in-vivo imaging. In 1998 he followed an offer of Schering AG to lead a research group at Justesa Imagen S.A. in Madrid, Spain as assistant manager and head of biological research and development in the field of X-ray contrast media research. In 2003 he moved back to Bayer Health Care Berlin (former Schering AG) and headed the group of early and mechanistic toxicology with research support for the early detection of safety liabilities of drug candidates and one year later headed the group of clinical pathology with the establishment of metabolic profiling technology in toxicology. Since 2005 he participated in the validation of new biomarkers within the HESI Nephrotoxicity Working Group. Beside the routine support and project related work the main area of interest are the application of metabolic profiling in toxicology and in pharmacological studies and the evaluation of new biomarkers for different organ toxicities in comparison to traditional endpoints of clinical pathology and histopathology in the context of toxicology testing.

Metabolic Profiling and Clinical Pathology

Dr. Jeff Patrick is the Director of Marketed Technology at LECO based in Saint Joseph, MI. He is responsible for applications, new products and marketing for their line of GC-TOF-MS Products. Prior to his role at LECO he was in the Pharmaceutical Industry as a leader in Bioanalytical Mass Spectrometry for 18 years. Jeff is a graduate of Purdue University (Ph.D. in Analytical Chemistry) where he studied with Graham Cooks and the University of South Carolina (M.S.) where he studied with John Baynes. Jeff has more than 30 publications and book chapters to his credit.

Scott Tebbutt is Associate Professor in the Department of Medicine, Division of Respiratory Medicine, University of British Columbia, and Principal Investigator at the James Hogg Research Centre, Institute for Heart + Lung Health, St. Paul’s Hospital, Vancouver, Canada. Since 2006, he has served as Co-Director of the Molecular Phenotyping and Genotyping Core of the James Hogg Research Centre, and he is currently Director of the Technology Development Core. He is also Chief Scientific Officer of the Prevention of Organ Failure (PROOF) Centre of Excellence, focused on heart, lung and kidney failure. Dr. Tebbutt earned his B.A. degree in Biochemistry from the University of Oxford (Oriel College), England in 1989, and his Ph.D. in Molecular Genetics from the University of East Anglia in 1993 (supervised by Dr. David Lonsdale, Cambridge Laboratory, John Innes Centre, England). He pursued post-doctoral fellowships in the laboratories of Professor Ann Harris (University of Oxford, Institute of Molecular Medicine) and Professor Diana Hill (University of Otago, Dunedin, New Zealand), where he studied the molecular genetics of cystic fibrosis. He was appointed Research Fellow at the University of Otago (1995-2001), leading a research team investigating the genomics of the sheep cystic fibrosis locus. He was seconded to a start-up biotechnology company (Global Technologies (NZ) Ltd.) as Director of Genomics (1999-2001). He moved to Canada in 2001, and was Senior Researcher in the Centre for Biomedical Research (University of Victoria, 2001-2002), prior to being recruited to the James Hogg Research Centre (formerly the iCAPTURE Centre) at St. Paul’s Hospital, Vancouver (2002).

Dr. Tebbutt’s research programme is focused on the genomics of complex respiratory disease, including the early and late reactions in allergic asthma and rhinitis. He also leads a multidisciplinary collaboration to investigate interactions between fungal spores and human airway cells. His research combines hypothesis-driven study of biological mechanisms with the development of advanced tools and technology (including bioinformatics and microfluidics-based systems) to better facilitate basic and translational research. Dr. Tebbutt has published original research contributions in journals such as the Proceedings of the National Academy of Sciences (U.S.A.), Journal of Medical Genetics, Genomics, BioTechniques, Bioinformatics, BMC Bioinformatics, BMC Medical Genomics and PLoS ONE. He has published numerous technical reviews as well as book chapters on the role of genetic variation in respiratory disease. He has served as reviewer on several grant panels, including the Canadian Institutes of Health Research and the Michael Smith Foundation for Health Research, and he is Associate Editor for the journal BMC Genetics. Dr. Tebbutt has received several fellowships and awards, including an Edward Penley Abraham Research Trust Fellowship (U.K.), a Journal of Cell Science Traveling Fellowship Award, and a Research Fellowship from the Cystic Fibrosis Association of New Zealand. He has been awarded competitive research funding from organizations such as the National Sanitarium Association (Canada), the British Columbia Lung Association, AllerGen NCE Inc. (Allergy, Genes and Environment Network), the Canadian Institutes of Health Research, the BC Proteomics Network, and the Wellcome Trust (U.K.).

Dr. Vladimir E. Bondarenko is Assistant Professor at Georgia State University, USA. He did his Ph.D. Physics and Mathematics, Moscow State University, Russia, 1990. Dr. Bondarenko’s research interests include dynamical systems, neuronal and cardiac cell models, neural networks, models of cardiac arrhythmias, ion channel models.

dynamical systems, neuronal and cardiac cell models, neural networks, models of cardiac arrhythmias, ion channel models.

Paul L Wood has completed his Ph.D. from Queen’s University and postdoctoral studies from the NIMH. He is the director of the Metabolomics Unit at Lincoln Memorial University and is professor of pharmacology and physiology. He has published more than 280 peer-reviewed papers, serves as Editor-in-Chief of Metabolomics, and is a member of the editorial board of the JAOA.

Utilization of metabolomics to study mechanisms of pathogenesis in neurogegeneration and oncology

Deliang Guo is an Assistant professor at Department of Radiation Oncology, James Comprehensive Cancer Center, The Ohio State University Medical Center.

EGFR signaling, lipid metabolism

As an NIH-funded translational scientist and an Associate Professor at Cedars-Sinai Medical Center, Dr. Jay Kim aims to improving the means of objectively diagnosing IC/PBS and to discover the mechanistic basis for this disorder. She was originally trained as a cancer biologist at Harvard Medical School, and is a rising leader of research on basic urological diseases including IC/PBS. One of the major focus areas in her group is the study of the metabolic signature for the diagnosis of IC/PBS, using a number of approaches, including large-scale “Omics” methods, to elucidate the signaling network in human cells that is perturbed in IC/PBS.

Cancer Biology,Biomedical Sciences, surgery

Preeti Bais is associate scientist at the Computational Sciences group at the Jackson Lab’s new research institute at University of Connecticut - JAX Genomics Medicine (JGM). It is an independent, nonprofi t organization focusing on mammalian genetics research to advance human health. She holds a Ph.D. in bioinformatics and computational biology and has worked in the metabolomics fi eld for many years including her tenure as a principal scientist at Stemina Biomarker Discovery, where she worked on many projects involving metabolomics analysis of Human Embryonic (hES) and Induced Pluripotent Stem (IPS) cells based assays for drug toxicity screening, autism biomarker detection using blood samples and cancer drug effi cacy testing using orthotropic mouse models of GBM.

Mass Spectrometry, Machine learning, bioinformatics , database , biomarkers

My current research focuses on combining metabolomics, a new and exciting post genomic technology with the power of bioinformatics tools for studying perturbations in metabolism caused due to changes in diet and/or the disease state. In one of our projects, we are investigating the change in the metabolomic patterns produced due to introduction of neutraceuticals in non-small cell lung carcinoma model. The NMR spectral data is subjected to Principal Component Analysis (PCA) to evaluate Biomarkers for early diagnosis of lung cancer. In another project, we are utilizing the metabolomics approach to observe alterations in metabolomics patterns in NMR spectra of biofluids (urine/plasma) from a spontaneous diabetes model. The change in metabolomic pattern or the biomarker profile will enable targeting of specific metabolic pathways affected by the disease condition, leading to mechanistic insight.

George G Chen is a professor in the Department of Surgery, Director of Surgical Research Laboratories, the Chinese University of Hong Kong, Hong Kong, China. He is also served as a principle investigator at the Hong Kong Cancer Institute. He has extensive experience in cancer research, particularly in the area of apoptosis in hepatocellular carcinoma, lung caner and thyroid cancer. He has authored or co-authored ~120 papers and has written a number of books or book chapters. He is currently a member of editorial boards or a guest editor of a number of scientific journals and a regular peer-reviewer for several grant agents. He was educated in China and United Kingdom and has MB and PhD degrees.

Metabolomics

Professor Alexander A. Kamnev is a Leading Scientist at the Institute of Biochemistry and Physiology of Plants and Microorganisms, Russian Academy of Sciences (Saratov, Russia). He received his Cand. Sci. (PhD equivalent; 1992) and DSc (2002) in physical chemistry from Saratov State University. Since mid-90s, his research has been focused on the application of various spectroscopic techniques in studying biomolecules, biocomplexes, supramolecular structures and microbial cells. Professor Kamnev is the main author of more than 100 papers in reputed international journals and several invited review chapters, serves as an editorial board member of a few international scientific journals and is involved in editorial and reviewing activities for a number of international specialized journals in the fields of chemistry and biology.

Zeeshan Ahmed works at the University of Wuerzburg with a strong interest in scientific software solution design and development. He is Post Doc. and Scientific Software Engineer and in the central computation support project of the collaborative research center SFB 1047 at the Biocenter, Department of Neurobiology and Genetics. He did Ph.D. in Bioinformatics from the University of Wuerzburg Germany in collaboration with Technical University of Munich Germany. Furthermore, he is also the alumni (pre. Doctoral research and degree course work) of Vienna University of Technology Austria, Fraunhofer Institute for Experimental Software Engineering Germany and Blekinge Institute of Technology Sweden.

Neurobiology and Genetics

Zuyi (Jacky) Huang completed his Ph.D. from Texas A&M University in 2010 and then worked as a Research Scientist in the Henry M. Jackson Foundation for the Advancement of Military Medicine. He joined the Department of Chemical Engineering at Villanova University as an Assistant Professor in 2011. He is now the Director of Computational Systems Biology Lab at Villanova University. He has published 18 papers in reputed journals. He is now serving as an editorial board member of Journal of Computer Science & Systems Biology. He is also serving on the International Federation of Automatic Control (IFAC) Policy Committee.

1) deriving quantitative data for transcription factors by analyzing GFP images and solving an inverse problem; 2)integrating available qualitative information into modeling by using Fuzzy logic;3) performing nonlinear model reduction of uncertain systems; 4) sensor network and experimental design for chemical plants.

Dr. Vicki has done MS Analytical Chemistry from University of Nebraska, PhD Analytical Chemistry, Iowa State University, Her research includes characterizing the small molecules in natural systems to understand how they interact synergistically in maintaining the energy balance in mammalian cells. As such, she have collaborated with other experts in the nutritional / biomedical area to link specific dietary metabolites to potential health outcomes. Her experience in dietary metabolites, background in pharmaceuticals, and education as a bioanalytical chemist provides the foundation needed to achieve her long term goals.

Synergistic interactions of secondary metabolites on maintaining the energy balance / fluxes in mammalian cells. Synergistic interactions of secondary metabolites of plant systems on phenotypic switches (e.g. inflammation (M1 to M2 states) and virulent bacteria). Effects of farming practices on secondary metabolites in various crops, with an emphasis on dry edible beans, strawberries, wheat and tomatoes. Development of high-throughput metabolomic analytical methods.

Dr Blair is a molecular biologist/ biochemist with 15 years experience in the pharmaceutical industry, recently as a Director of Applied Diagnostics and Surrogates at GlaxoSmithKline, and is a visiting scholar at Cambridge University.

He has been involved in all aspects of early phase drug development from target identification & routine compound screening through to pre-clinical development & Phase II clinical trials. He has developed programmes that support the strategic integration of surrogate biomarkers & diagnostics into the drug development pipe-line from candidate selection to approval & launch. His broad therapeutic area experience includes viral, respiratory, liver and neurodegenerative disease, frequently in collaboration with esteemed academic groups and he was an initial recruit to the GSK Predictive Medicine Group, where he lead pioneering work on integration of testing with influenza, herpes and hepatitis C virus drug development. He is an expert in the field of virology having published more than 30 papers, edited two books and invented 6 patents in the field.

Paul L Wood has completed his Ph.D. from Queen’s University and postdoctoral studies from the NIMH. He is the director of the Metabolomics Unit at Lincoln Memorial University and is professor of pharmacology and physiology. He has published more than 280 peer-reviewed papers, serves as Editor-in-Chief of Metabolomics, and is a member of the editorial board of the JAOA.

Utilization of metabolomics to study mechanisms of pathogenesis in neurogegeneration and oncology

Dr. Shane Rea did his Post Doctoral from McGill University of Colorado.

The goal of the research in the Rea laboratory is to understand the causes of human aging at a molecular genetic level and to use this information to slow the aging process. Dr. Rea’s research group utilizes the nematode Caenorhabditis elegans and focuses specifically on the Mit mutants, which (paradoxically) have disruptions in their mitochondrial electron transport chain yet are long-lived. This model is short-lived (~20 days), self-fertilizing, genetically powerful, easily and cheaply cultivated, and provides excellent molecular and bioinformatic resources. Twenty-five percent of worm genes have human orthologues. Pathways already known to influence aging in C. elegans act similarly in humans (e.g., insulin/IGF-1 like receptor). Mitochondria function similarly in almost all eucaryotes. Life extension in the Mit mutants is restricted to a specific window of mitochondrial dysfunction. The Mit mutants provide a new model for several human mitochondrial-associated diseases. Nuclear DNA damage, cell-cycle checkpoint functions, alternate metabolic pathways, and ROS signalling appear to be central players in lifespan regulation of the Mit mutants. The Rea laboratory also explores the connection between functionally impaired mitochondria, nuclear checkpoint proteins and life extension in the Mit mutants. This research team performs metabolic fingerprinting of the Mit mutants as well as the biochemical and biophysical characterization of the mitochondria from long-lived and short-lived mitochondrial mutants. This group also investigates compensatory biochemical mechanisms that act to offset partial mitochondrial inhibition. They strive to translate their work into higher eucaryotes and to ameliorate human mitochondrial-associated diseases.

Daniel Kassel is an entrepreneur and Founder for SciAnalytical Strategies, Inc. He did his PhD in Chemistry/Bioanalytical from Michigan State University.

Adipocyte Therapeutics

Chris Beecher was a member of the Department of Pathology, University of Michigan School of Medicine until 2011 when he founded NextGen Metabolomics. He was also one of the founders of Metabolon, and Metabolic Analyses. His Ph.D. was granted in 1985 in Pharmaceutical Sciences specializing in Natural Products drug discovery. He has more than 25 years of experience in metabolomics and drug discovery and development, has published over 80 peer-reviewed papers, and is listed as the inventor of 8 patents in metabolomics.

Metabolomics, Chemistry (Natural Products, Analytical, and Physical), Biochemistry, Informatics, Statistics. The development of Metabolomics as the basis of Health Care in the future, and as a research tool in the present

Jeffrey S Patrick has completed his Ph.D. at Purdue University under the guidance of Prof. Graham Cooks. After more than 15 years in biological mass spectrometry and biomarker research, he is currently the Director of Marketed Technology at LECO, a manufacturer of high performance time of flight mass spectrometers. He has published more than 40 papers in reputed journals and presented more than 50 orals at global conferences.

Analytical Chemistry, Chromatography, Proteomics, GC-MS

Dr. D. Marshall Porterfield is now serving as Division Director for Space Life and Physical Sciences in the Human Exploration and Operations Mission Directorate at NASA headquarters in Washington DC. The division includes the Human Research Program, the Physical Sciences Program, and the Space Biology Program, as well as acting as the liaison for the ISS National Lab. The SLPS program includes responsibility for managing all extramural grants and research, as well as the intramural research and engineering assets at six NASA centers. Currently the programmatic focus is on ISS utilization. Dr. Porterfield is on official leave from Purdue University where he is a Professor of Biological Engineering.His teaching and research focus is on advanced physiological sensing technologies for research applications in biology, agriculture, the environment, and medicine. Several of his recent projects involve scanning probe sensor technology, biosensors, bio-MEMS, bio-nanotechnology, and lab-on-a-chip systems. He also is working on understanding how living systems adapt and respond to the spaceflight environment. His work in gravitational and space biology includes cell signaling, biophysical limitations in microgravity, nutrient delivery technology, and biomimetic sensors. He was recognized by the American Society for Gravitational and Space Biology in 2007 with the Halstead Young Investigator Award. Overall his research work at Purdue was recognized by the University Faculty Scholar Award, the University’s top mid career research distinction. His work includes publishing over 100 peer reviewed manuscripts, papers, technical publications, patents, and book chapters; he has also delivered almost 100 invited presentations.His leadership activity includes service as President of the American Society for Gravitational and Space Biology, and he was also recently elected to serve as President for the Institute for Biological Engineering.Dr. Porterfield’s work in the field of biological engineering was recently recognized by election to the College of Fellows for the American Institute for Medical and Biological Engineering, an honor reserved forthe top 2% of medical and biological engineers in US. He was cited for his work \\\\\\\"bridging the interface between engineering and physiology through outstanding contributions to biosensor technology and fundamental cell biology.\\\\\\\"

Advanced physiological sensing technologies for research applications in biology, agriculture, and medicine. Specific projects include: scanning probe sensor technology, biosensors, bioMEMS, bionanotechnology, and lab-on-a-chip systems. He also is working with plant systems in bioregenerative life support systems for spaceflight. His work in this area includes cell signaling, biophysical limitations in microgravity, nutrient delivery technology, and biomimetic sensors.

Ralph Zahn joined BIOCRATES in October 2010 as chief technology officer for the further development of the product pipeline and the affiliated technical and scientific assignments. He holds a PhD in natural science and has a wealth of experience in the field of biotech. After he graduated from biology, he worked as research associate and earned the doctors degree in 1994 at the Max-Planck-Institute for Biochemistry in Munich. At the Cambridge University he obtained a post-graduate doctor degree. He habilitated 2001 at the Institute for Molecular Biology and Biophysics at the Eidgenössischen Technischen Hochschule in Zurich. During his career, he was managing director at BioSafety GmbH and founder and CEO of allprion AG.

NMR structure of the bovine prion protein, NMR structures of three single-residue variants of the human prion protein, metabolomic Buiomarker Research, Molecular Biology and Biophysics

Irwin J Kurland, MD, Ph.D. is an Associate Professor of Medicine, and Director of the Stable Isotope and Metabolomics Core Facility at the Albert Einstein College of Medicine. Dr Kurland\'s laboratory has helped, for over a decade, to establish stable isotope phenotyping methodology for assessing inter-organ fuel switching. Recent papers by the Kurland laboratory illustrate the regulatory role of lysine acetylation on enzymes in tissue specific metabolic networks (Yang et al., J. Proteome Res. 2011), and the linkage between disturbances in fasted/re-fed acetyl CoA levels and dysregulated global lysine acetylation, on the fasted/re-fed metabolic network response (Vaitheesvaran et al., PLOS One 2012).

Diabetes, Metabolomics Syndrome,GC/MS flux profiling,Gas chromatography/Mass spectrometry (GC/MS).

Dr. SivanesanDakshanamurthyis an Associate Professor in the Departments of Oncology and Experimental & Clinical Therapeutics, Georgetown University Medical Center. My area of expertise is multi-disciplinary in nature such as drug design (in-silico/in-vitro), chemo-and clinical-informatics, metabolomics, molecular biology and medicinal chemistry. I have published more than 53 peer reviewed journal articles and have 10 patents issued/applied.

High-throughput chemo-informatics, drug-repurposing, drug-protein docking, and molecular dynamics simulations

Dr. Karp has been a bioinformatics researcher for over 10 years in the areas of bioinformatics databases, metabolic-pathway bioinformatics, and database interoperation. He has authored numerous publications on these topics, and is the developer of the EcoCyc database, and the Pathway Tools software. EcoCyc is a database describing the genome and biochemical machinery of the bacterium E. coli. The Pathway Tools is a software environment for constructing, querying, and WWW publishing of pathway/genome databases such as EcoCyc. Dr. Karp\'s bioinformatics research has been funded by the NIH National Center for Research Resources and National Library of Medicine.

Bioinformatics databases, Metabolic-pathway Bioinformatics, and database Interpretation.

Danilo Tagle, Ph.D., is Program Director for Neurogenetics at the National Institute of Neurological Disorders and Stroke (NINDS), where he is involved in developing programs in genomics and proteomics for basic and translational research in inherited brain disorders. Dr. Tagle obtained his Ph.D. in molecular biology and genetics from Wayne State University in 1990. He was a National Institutes of Health (NIH) National Research Service Award (NRSA) postdoctoral fellow in human genetics in the laboratory of Dr. Francis S. Collins at the University of Michigan. Prior to joining NINDS in 2001, Dr. Tagle was an investigator and Section Head of Molecular Neurogenetics at the National Human Genome Research Institute (NHGRI) since 1993 and was involved in the positional cloning of genes for Huntington disease, ataxia-telangiectasia, and Niemann-Pick type C disease.

Dr. Tagle was an intramural investigator and Section Head of Molecular Neurogenetics at the National Human Genome Research Institute (NHGRI) since 1993 and was involved in the positional cloning of genes for Huntington disease, ataxia-telangiectasia, and Niemann-Pick type C disease.

Preeti Bais holds a BS in computer Science from National Institute of Technology (Bhopal, India), MS in Bioinformatics from Brandeis University (Waltham, MA) and a PhD in Bioinformatics and Computational Biology with a minor in Statistics from Iowa State University (Ames, Iowa). For her PhD work, she combined data from 11 different GCMS and LCMS based platforms on 70 single gene knock out mutants of Arabidopsis to create the plantmetabolomics.org database and metabolomics data analysis pipeline. As a principal scientist at Stemina Biomarker Discovery (Madison, WI), she used metabolomics and stem cell technology for drug toxicity screening studies, NCI funded metabolomics analysis of mouse in-vivo assays to understand drug efficacy in human GBM (Glioblastoma multiforme), and metabolomics analysis of patient blood samples to detect autism. She has recently joined the computational sciences and statistical analysis group at the Jackson lab’s new research institute - JAX Genomics Medicine (JGM) at University of Connecticut (Farmington, CT). This independent, nonprofit organization focuses on mammalian genetics research to advance human health and has been working in various disease areas like cancer, neurodegenerative disorders to name a few.

Developing metabolomics as a systems biology tool, statistical analysis, pattern recognition, metabolic network analysis, plant metabolomics, data analysis pipeline development, metabolomics standards

Wei Jia is Professor and Co-Director of the Center for Translational Biomedical Research, the University of North Carolina-Greensboro. He also serves as Director of the Metabolomics Core Lab at the David H Murdock Research Institute, Kannapolis, North Carolina. Jia was previously Professor and Vice Dean, School of Pharmacy, Shanghai Jiao Tong University in China, and has worked nearly a decade on biochemical profiling of botanical preparations and metabolomics. Professor Jia’s current research focuses on mass spectrometry (MS)-based metabolomics profiling technologies to investigate metabolic phenotypes and metabolic transformation in cancer and metabolic disorders.

Metabonomic study of disorders, including diabetes, obesity, and colorectal cancer.

Zuyi (Jacky) Huang completed his Ph.D. from Texas A&M University in 2010 and then worked as a Research Scientist in the Henry M. Jackson Foundation for the Advancement of Military Medicine. He joined the Department of Chemical Engineering at Villanova University as an Assistant Professor in 2011. He is now the director of Computational Systems Biology Lab at Villanova University. He has published 18 papers in reputed journals. He is now serving as an editorial board member of Journal of Computer Science & Systems Biology. He is also serving on the International Federation of Automatic Control (IFAC) Policy Committee.

1) deriving quantitative data for transcription factors by analyzing GFP images and solving an inverse problem; 2)integrating available qualitative information into modeling by using Fuzzy logic;3) performing nonlinear model reduction of uncertain systems; 4) sensor network and experimental design for chemical plants

Ryals received his Ph. D. in Molecular Biology from the University of Texas at Dallas in 1982. Following post doctoral work in the lab of Charles Weissmann at the Institute for Molecular Biology at the University of Zurich, Ryals joined Ciba-Geigy in the Biotechnology Research Unit at Research Triangle Park (now Syngenta). Ryals worked in various research and management positions including Head, Agricultural Biotechnology Research, Vice-President of Biotechnology, Vice-President, Research for Novartis Crop Protection, Inc. and Head of the Biotechnology and Genomics Center of Novartis, Inc. In 1997, Ryals founded Paradigm Genetics, Inc., an early systems biology company, and served as the Chief Executive Officer, Chief Science Officer and President and taking the company public in 2000. After leaving Paradigm Genetics in 2002, Ryals joined Metabolon, Inc. as Chief Executive Officer and President. For the past 10 years, Ryals research interest has been in the development of metabolomics to aid in pharmaceutical drug discovery and development, healthcare and nutrition. Metabolon, Inc. is a diagnostics and commercial services company offering the industry’s leading biochemical profiling platform. Metabolon has performed over 2000 studies to date with involving more than 500 customers and collaborators. Among these studies, Metabolon has conducted over 300 studies on cancer and in particular in contrasting various types of cancer and discovering biomarkers that can be used to differentiate various forms of the disease.

Development of metabolomics to aid in pharmaceutical drug discovery and development, healthcare and nutrition.

She has done MS Analytical Chemistry from University of Nebraska, Ph.D. Analytical Chemistry, Iowa State University, Her research includes characterizing the small molecules in natural systems to understand how they interact synergistically in maintaining the energy balance in mammalian cells. As such, she have collaborated with other experts in the nutritional/biomedical area to link specific dietary metabolites to potential health outcomes. Her experience in dietary metabolites, background in pharmaceuticals, and education as a bioanalytical chemist provides the foundation needed to achieve her long term goals.

Synergistic interactions of secondary metabolites on maintaining the energy balance / fluxes in mammalian cells. Synergistic interactions of secondary metabolites of plant systems on phenotypic switches (e.g. inflammation (M1 to M2 states) and virulent bacteria). Effects of farming practices on secondary metabolites in various crops, with an emphasis on dry edible beans, strawberries, wheat and tomatoes. Development of high-throughput metabolomic analytical methods.

Xue-Long Sun is an Associate Professor and has been promoted to a Full Professor (2012) in the Department of Chemistry, Cleveland State University and holds an adjunct faculty position at the Department of Molecular Cardiology, Cleveland Clinic since 2007. Dr. Sun earned his Ph.D. degree in Pharmaceutical Chemistry from Kitasato University School of Pharmacy, Tokyo, Japan. He has published 73 peer-reviewed research articles and book chapters. He has been trained as carbohydrate chemist working on synthesis and characterization of sialic acid derivatives during graduate research and glycosaminoglycan mimetics during postdoctoral research. Recently, he is working on glyco-macroligand-based microarray and biosensor for proteomics, pathogen identification; glyco-affinity macroligand engineering for glycoproteomics and glycomics research. In addition, he has worked on synthesis and characterization of lipid and glycolipid derivatives for more than ten years. He has been a Guest Editor for a Special Issue (2010, 30 (2)) of Carbohydrate Recognition and Applications for Medicinal Research Reviews (Wiley InterScience).

Metabolomics

Laszlo Vigh, Director, Hungarian Academy Of Sciences.

Leucocyte research and molecular and chemical patterns.

Ralph Zahn joined BIOCRATES in October 2010 as chief technology officer for the further development of the product pipeline and the affiliated technical and scientific assignments. He holds a PhD in natural science and has a wealth of experience in the field of biotech. After he graduated from biology, he worked as research associate and earned the doctors degree in 1994 at the Max-Planck-Institute for Biochemistry in Munich. At the Cambridge University he obtained a post-graduate doctor degree. He habilitated 2001 at the Institute for Molecular Biology and Biophysics at the Eidgenössischen Technischen Hochschule in Zurich. During his career, he was managing director at BioSafety GmbH and founder and CEO of allprion AG.

Viktor Stolc is the director of the NASA Ames Genome Research Facility (Mountain View, CA), where he has pioneered the development of large-scale functional genomics projects, including high resolution tiling arrays for the entire human genome and various model organisms. Prior to joining NASA in 2000, Stolc worked as a Damon Runyon Cancer Research post-doctoral fellow at Stanford University Genome Technology Center (Palo Alto, CA), where he co-invented a method for direct multiplex characterization of genomic DNA. Dr. Stolc received his doctoral degree from Yale University School of Medicine, Department of Cell Biology (New Haven, CT), where he identified and characterized nuclear RNase P protein components from humans and yeast.

Characterization of dynamic sequence variations caused by metabolic oxidation, and identification of the physical basis for universal feedback mechanism between heredity and the environment.

Laura Bindila is Scientist within Luxembourg Clinical Proteomics laboratory, at the Centre de Recherche Publique de la Sante, Strassen, Luxembourg. She carried out her PhD program at University of Munster, Institute for Medical Physics and Biophysics and defended her thesis at the Babes Bolyai University of Cluj Napoca, Romania. She continued her potdoctoral and scientific career at the University of Munster till January 2010 when she moved to Luxemborug Clinical Proteomics laboratory. She has published more than 25 articles, including reviews. She has teaching experience of more than 5 years. She is member of graduate school in Molecular and Cellular Glyco-Sciences (University of Munster) and served as member in Erasmus exchange programs between european universities. She served as a reviewer of peer-reviewed journals in the area of glycobiology, lipidomics and proteomcis. She is member of organizing committee of the Summer School for Mass Spectrometry in Biotechnology and Medicine. She received the Summa cum laudae title for her PhD thesis.

Metabolomics

Mukesh Verma is a Program Director and Chief in the Methods and Technologies Branch (MTB), Epidemiology and Genetics Research Program (EGRP) of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI), National Institutes of Health (NIH). Before coming to the DCCPS, he was a Program Director in the Division of Cancer Prevention (DCP), NCI, providing direction in the areas of biomarkers, early detection, risk assessment and prevention of cancer, and cancers associated with infectious agents. Mukesh Verma holds a M.Sc. from Pantnagar University and a Ph.D. from Banaras Hindu University. He did postdoctoral research at George Washington University and was a faculty member at Georgetown University. He has published 125 research articles and reviews and edited four books in cancer epigenetics and epidemiology field. Verma has developed concepts (PA and RFA) on exfoliated cells and circulating DNA and their application in cancer detection and risk assessment, cancer epidemiology, risk prediction models in cancer, mitochondrial DNA and cancer epidemiology, cancer epigenetics, pancreatic cancer etiology, AIDS related malignancies, and systems genetics. Verma represents NCI in NIH Common Funds Metabolomics and NIH Roadmap Epigenomics. He also served as the Project Officer for an Inter Agency Agreement with CDC with focus on biomarkers of cervical cancer.

Cancer epidemiology, risk prediction models in cancer, mitochondrial DNA and cancer epidemiology, cancer epigenetics, pancreatic cancer etiology, AIDS related malignancies, and systems genetics.

George G Chen is a professor in the Department of Surgery, Director of Surgical Research Laboratories, the Chinese University of Hong Kong, Hong Kong, China. He is also served as a principle investigator at the Hong Kong Cancer Institute. He has extensive experience in cancer research, particularly in the area of apoptosis in hepatocellular carcinoma, lung caner and thyroid cancer. He has authored or co-authored ~120 papers and has written a number of books or book chapters. He is currently a member of editorial boards or a guest editor of a number of scientific journals and a regular peer-reviewer for several grant agents. He was educated in China and United Kingdom and has MB and PhD degrees.

Metabolomics

Mario Hugo Genero, MD is a cofounder and scientific Director of BMG BioPharma. He has received a MD degree from Buenos Aires University, Buenos Aires, Argentina (1990). Adjunct professor of Medical Genetics, Austral University (2005-2009). He has served as Council Member of The Human Proteome Project (HUPO) for two period (2003-2009). He is serving as coordinator of the Latin America HUPO. He is participating in the cardiovascular Initiative at HUPO. He also is serving at the Education and Training Committee of The Human Proteome Project (HUPO) as coordinator of specific educational needs of “Proteomics less advanced countries”.

Medical Genetics,Vascular Therapy

Vidya Velagapudi obtained her PhD in Applied Biochemistry from Univresity of Saarland in collaboration with the Max-Plank Institute for Informatics, Germany in 2005. Later on she moved to VTT, Finland as a post-doctral fellow and continued as a Research Scientist and Project manager during 2006-2009. In 2010, Dr. Velagapudi has taken up the role of Head of the Metabolomics Unit at Institute for Molecular Medicine Finland (FIMM). From 2012 omwards Dr. velagapudi is also affiliation to University of Helsinki as an Adjunct professor. Dr. Velagapudi has published more than 25 scientific articles in international journals and also acting as editorial board member and reviewer for the journals in the field of metabolomics.

Metabolomics

Professor Alexander A. Kamnev is a Leading Scientist at the Institute of Biochemistry and Physiology of Plants and Microorganisms, Russian Academy of sciences (Saratov, Russia). He received his MSc in chemistry (1980), Cand. Sci. (PhD equivalent; 1992) and DSc (2002) in physical chemistry from Saratov State University. His scientific background included chemistry and electrochemistry of transition-metal hydroxide materials.

Plant Biochemistry

Studied in Politechnica University of Timisoara

Automation and Applied Informatics

John A. McLean is an Assistant Professor in the Department of Chemistry at Vanderbilt University and a faculty fellow in the Institute of Chemical Biology and Institute of Integrative Biosystems Research and Education. His recent awards include an Excellence in Teaching Award from the student members of the American Chemical Society, a Defense Threat Reduction Agency Research Award, an American Society for Mass Spectrometry Research Award, a Spectroscopy Society of Pittsburgh Award, an R&D 100 Award, and the Bunsen–Kirchhoff Prize from the GDCh. He has published over 60 manuscripts in the peer-reviewed literature, 8 book chapters, and 15 patents.

Chemical Biology

Guanyu Wang has completed his Ph.Ds from Zhejiang University in 1998 and from University of Cologne in 2005. He completed his postdoctoral studies from University of Texas Health Science Center at Houston, Rice University. He is now an assistant professor of Physics at George Washington University. He has published more than 30 papers in reputed journals and serving as an editorial board member of Journal of Biochemistry and Analytic Biochemistry.

Analytic Biochemistry

Neil Price is a government research scientist at the USDA’S National Center for Agricultural Utilization Research (USDA-NCAUR) in Peoria, IL. He has a Ph.D. in biochemistry from the University of London (1990), and research experience at the John Innes Institute, Norwich, U.K., University of Geneva, Switzerland, and Paul-Sabatier University in Toulouse, France, before joining the Complex Carbohydrate research Center in Athens, GA. He previously held a faculty position at the Dept. of Pharmacology, U. of Rochester, NY, before joining the USDA-NCAUR national laboratory in 2003. EMBO fellowship (1990); CNRS-INRA (France) Postdoctoral Fellowship (1991); Procter and Gamble Exploratory Research Prize (1997); American Society for Biochemistry and Molecular Biology (ASBMB, 1994 – present); American society for Mass Spectrometry (2003 –present).

Plant Biochemistry, Mass Spectromerty

Alan Prem Kumar earned his PhD from University of North Texas, USA. From his PhD work, he discovered a novel regulatory protein, PyrR for pyrimidine biosynthetic pathway in Pseudomonas, Because pyrimidine biosynthesis is an essential step in the progression of secondary Pseudomonas infection, PyrR presents an attractive anti-Pseudomonal drug target. Dr. Kumar then pursued Postdoctoral training in Cancer Research at Sidney Kimmel Cancer Center, California, USA. He was awarded a postdoctoral Fellowship for his work on the role of nuclear receptors in the transcriptional regulation of human myeloperoxidase, a leukocyte enzyme implicated as causative agent in atherosclerosis and Alzheimer’s disease. Dr. Kumar relocated back to Singapore to join the Faculty of Medicine, National University of Singapore as an independent Principal Investigator to continue on his expertise on nuclear receptor amd cancer biology. His current research interest includes the role of nuclear receptors involved in the regulation of target genes and elucidate mechanism and association signal pathways. Another area of interest is aimed at developing new derivative drugs with hopefully fewer side effects.

Metabolomics